Clinical Trials
15 trialsNCT05294900 2026-05-26
NEOS
Yonsei University
Phase 2 Completed
NCT02254278 2026-05-22
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
NRG Oncology
Phase 2 Completed
NCT02308072 2026-05-22
ORCA-2
University College, London
Phase 1 Completed
NCT03336606 2026-05-22
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
Phase 1 Completed
NCT03789097 2026-05-22
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT03650764 2026-05-15
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
Phase 1/2 Completed
NCT05278039 2026-05-14
Training Swallowing Initiation During Expiration
Northwestern University
Phase NA Completed
NCT02841748 2026-05-13
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
University of Chicago
Phase 2 Completed
NCT04369937 2026-05-13
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
Phase 2 Completed
NCT04354246 2026-05-12
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
Phase 1 Completed
NCT02296684 2026-05-08
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
Phase 2 Completed
NCT03552718 2026-05-07
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience, Inc.
Phase 1 Completed
NCT04199104 2026-05-05
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04665843 2026-05-05
SKYSCRAPER-09
Hoffmann-La Roche
Phase 2 Completed
NCT06094829 2026-05-05
DEMO
Hospices Civils de Lyon
Completed